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676Objectives: To review the current state of clinical practice and discuss recent advances in the diagnosis andman-
agement of acute kidney injury (AKI) in the context of cardiac surgery.
Methods: A review of the published data pertaining to AKI in the setting of cardiac surgery and cardiothoracic
surgical critical care medicine was conducted, and the relevant data were synthesized from appropriate interven-
tional and observational study reports.
Results: Significant advances have occurred in the diagnosis of AKI, and consensus has been reported on a sys-
tem of diagnosis using the serum creatinine and urine output. New biomarkers of injury and function are avail-
able that are likely to improve the interval to diagnosis of AKI after cardiac surgery. The adverse effect on
outcome of small changes in serum creatinine is appreciated. Novel prevention and rescue therapies are now
entering phase I and II studies. Urinary alkalinization was effective in a phase II blinded clinical trial and is
now the subject of a multicenter, double-blind, randomized clinical trial of cardiac surgery patients.
Conclusions: In 2011, the field of AKI could be emerging from a period of stagnation that has lasted more than 2
decades. The failure to translate successful animal model interventions to the clinic might have resulted from
delays in diagnosis that might now be avoidable with the advent of novel diagnostic biomarkers. (J Thorac Car-
diovasc Surg 2012;143:676-81)Acute renal failure is now referred to as acute kidney injury
(AKI)—a term used widely throughout nephrology and crit-
ical care medicine. It has been adopted to focus attention on
the spectrum of the illness, ranging from a minor change in
serum creatinine or a brief period of oliguria to acute tubular
necrosis requiring renal replacement therapy (RRT). A
widely agreed conceptual model of AKI1 has been pub-
lished and is reproduced in Figure 1.
In the present report, recent studies of the epidemiology
of AKI after cardiac surgery2 have been reviewed and the
new consensus diagnostic systems of Risk, Injury, Failure,
Loss, End-Stage Renal Disease (RIFLE)3 and Acute Kidney
Injury Network (AKIN) are discussed.4 The novel bio-
markers of both kidney injury and declining kidney function
have also been reviewed and the existing and novel treat-
ment strategies summarized. The present report is a sum-
mary of a presentation during the Critical Care Seminar
held at the 2010 meeting of the American Association for
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The Journal of Thoracic and Cardiovascular SurgEPIDEMIOLOGY OF CARDIAC-ASSOCIATED AKI
We have known for years that cardiac surgery is an im-
portant risk factor for acute kidney injury. Reports from
several groups have described the incidence and prognostic
importance of cardiac surgery-associated AKI for clinical
outcomes in adult2,5 and pediatric6 cardiac surgical patients,
and these have been placed both in the context of the spe-
cific operation performed7 and the type of practice. It is
now understood that the overall incidence of AKI after adult
cardiac surgery is about 5% to 10%7 and is highly depen-
dent on pre-existing renal function and the complexity of
the proposed surgery.8 Several clinical risk factors have
been consistently reported, and these are summarized in
Table 1. The importance of acquired comorbid disease is
clear in AKI, but the role of genetic variation as a determi-
nant of both risk and outcome is much less well defined. It is
probable that a patient’s DNA sequence variants have more
of an effect on host repair and regeneration biology than on
the risk of AKI per se.9
Swaminathan and colleagues5 recently reviewed the Na-
tional Inpatient Sample database and reported that the inci-
dence of AKI after cardiac surgery appears to have
increased in recent years. They pointed out that the inci-
dence of new dialysis has not changed (still about 1% over-
all); thus, the likely reason for this finding is a loosening of
the diagnostic criteria such that the AKI label is now applied
more readily to patients with lesser reductions in kidney
function. The significance of this was noted first by Chertow
and colleagues,10 who noted an adverse effect on outcome
in patients with seemingly trivial increases in serum creat-
inine. The validation of the new RIFLE criteria of Bellomo
and colleagues3 in more than 500,000 patients underscoresery c March 2012
FIGURE 1. Conceptual model of acute kidney injury (AKI). GFR,
Glomerular filtration rate. Reproduced from Murray and colleagues,1
with permission.
Abbreviations and Acronyms
AKI ¼ acute kidney injury
AKIN ¼ Acute Kidney Injury Network
KIM-1 ¼ kidney injury molecule 1
NGAL ¼ neutrophil gelatinase-associated
lipocalin
RRT ¼ renal replacement therapy
RIFLE ¼ Risk, Injury, Failure, Loss, End-Stage
Renal Disease
Shaw Perioperative Managementthis concept. Also, it is important for surgeons to appreciate
the significance of a small (0.3 mg/dL) increase in serum
creatinine in their patients.
The type of surgery performed has relevance for both the
risk of AKI and the pattern of serum creatinine likely to oc-
cur in the immediate postoperative period.7 It is now appre-
ciated that patients undergoing complex, on-pump surgery
(ie, anythingmore than primary CABG) have a significantly
greater risk of postoperative AKI and also have a greater in-
cidence of severe AKI needing dialysis. In most instances,
the serum creatinine decreases by about 0.1 to 0.2 mg/dL af-
ter cardiac surgery,11 and when it does not, this should raise
awareness of the possibility of additional increases. If the
creatinine increases by as little as 0.3 mg/dL within a 48-
hour period, the patient has stage 1 AKI according to the
AKIN criteria (see below).TABLE 1. Clinical risk factors for cardiac surgery-associated acute
kidney injury
Reduced preoperative renal function
Advanced age
African-American ethnicity
Increased body weight
Pulse pressure hypertension
Peripheral vascular disease
Diabetes mellitus (and metabolic syndrome)
Reduced left ventricular function
Anemia
Blood transfusion
Revision surgery
Aortic surgery
Poor intraoperative blood pressure control
Prolonged cardiopulmonary bypass
P
MAKI DIAGNOSIS
Traditionally, clinicians have referred to acute renal
failure as a clinical situation that leads to a decline in re-
nal function such that nitrogenous waste accumulates in
the circulation and manifests as azotemia. This can be ac-
companied by oliguria or anuria and might or might not
require renal replacement therapy, traditionally in the
form of intermittent hemodialysis. Each new study ad-
dressing acute renal failure used different diagnostic crite-
ria,12 and it was unclear how to compare the results across
studies, across patient populations, and across interven-
tions. In May 2002, the Acute Dialysis Quality Initiative
group assembled stake holders to attempt to reach a con-
sensus in the definition. The report of that meeting3 de-
scribed the RIFLE criteria (Figure 2). RIFLE has since
been validated in more than 500,000 patients across mul-
tiple disease and referring (primary) medical specialties. It
is a robust diagnostic system that has allowed the compar-
ison of incident rates and intervention effect sizes and was
the platform on which the AKIN criteria4 were based
(Table 2). The AKIN introduced an absolute increase of
0.3 mg/dL to the diagnostic criteria for stage 1 disease,
in addition to the 50% increase option published in
RIFLE. Either are suitable for both clinical and researchThe Journal of Thoracic and Capurposes, and in some intensive care units, their presence
or absence is documented daily.
However, changes in serum creatinine occur late in the
development of AKI—typically 48 hours after the initiating
event (surgery in the case of cardiac surgery-associated
AKI).13 An earlier diagnosis would surely assist with treat-
ment and, even in the absence of demonstrably effective
therapies, would at least permit avoidance of dehydration,
excessive diuretic prescription, and other nephrotoxic inter-
ventions. Such timely diagnosis might be available shortly
with the advent of novel biomarkers of both kidney injury
and declining function. An exhaustive review was beyond
the scope of the present report, but many excellent reviews
are available on this topic.14,15 A brief summary of the
biomarkers most likely to have the earliest impact is
appropriate and follows below, with emphasis on
neutrophil gelatinase-associated lipocalin (NGAL), kidney
injury molecule 1 (KIM-1), and cystatin C.
NEUTROPHIL GELATINASE-ASSOCIATED
LIPOCALIN
NGAL is a naturally occurring protein found in tissue and
circulating in very low concentrations in the plasma. In car-
diac surgery-associated AKI, it has been shown to berdiovascular Surgery c Volume 143, Number 3 677
FIGURE 2. Risk, Injury, Failure, Loss, End-Stage Renal Disease (RIFLE) criteria.GFR, Glomerular filtration rate; SCr, serum creatinine;ESKD, end-stage
kidney disease. Reproduced from Bellomo and colleagues,3 with permission.
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Melevated very early after surgery (2 hours after cardiopul-
monary bypass in some reports), and both urinary and
plasma assays are available.13 The tests are available for
clinical use in Europe and will eventually also be available
for use in North America. It is currently unclear which test
provides the best diagnostic performance for AKI, but there
is some suggestion that the combination of the two tests
might be better than either alone. In general, urine is an at-
tractive proximal fluid for kidney biomarker discovery and
development, because tubular proteins leaking from dam-
aged nephrons are concentrated, rather than diluted, as is
the case in plasma. It is also probable that plasma NGAL
is a closer reflection of systemic inflammation than theTABLE 2. AKIN criteria for diagnosis of AKI
Stage Serum creatinine criteria
1 Increase in serum creatinine of 0.3 mg/dL or increase to 
(1.5–2-fold) from baseline
2 Increase in serum creatinine to>200–300% (>2–3-fold) fro
3 Increase in serum creatinine to>300% (>3-fold) from base
creatinine of4.0 mg/dL, with acute increase of0.5 mg/
AKI, Acute kidney injury; AKIN, Acute Kidney Injury Network.
678 The Journal of Thoracic and Cardiovascular Surgextent of renal injury inflicted.16 It is certain that once intro-
duced into clinical practice, observational studies of this
novel test will define its role in our diagnostic armory
more clearly. In the meantime, it has great potential for
use in intervention trials as a way of enriching the study
population for randomization of putative interventions.
KIDNEY INJURY MOLECULE 1
KIM-1 is a transmembrane protein present in the renal
proximal tubule whose expression is markedly upregulated
in response to acute ischemia or exposure to nephrotoxins.
Although several reports from noncardiac surgical patient
populations have shown that KIM-1 appears to be a veryUrine output criteria
150–200% <0.5 mL/kg/hr for>6 hr
m baseline <0.5 mL/kg/hr for>12 hr
line, serum
dL, or any dialysis
<0.3 mL/kg/hr for 24 hr or anuria for 12 hr
ery c March 2012
Shaw Perioperative Managementsensitive indicator of AKI,17 fewer cardiac surgery studies
have been published. In one study of 103 adult patients un-
dergoing cardiopulmonary bypass, the KIM-1 levels were
significantly increased at both 2 and 24 hours after surgery
in patients who subsequently developed AKI.18 In a recent
review, KIM-1 was found to be a useful diagnostic assay for
AKI after cardiac surgery but was less sensitive for predict-
ing the need for dialysis or death.19CYSTATIN C
Cystatin C is a ‘‘housekeeping’’ protein that is produced
continuously by all nucleated cells. Because it is freely fil-
tered at the glomerulus, is completely reabsorbed by the
proximal convoluted tubule, and is not secreted, it has qual-
ities that make it suitable for measuring the glomerular fil-
tration rate.20 Compared with serum creatinine, it is less
affected by age, gender, and body weight. In one prospec-
tive study, cystatin C and NGAL were measured in both
the plasma and urine of 72 adults undergoing cardiac sur-
gery.21 Within the first 6 hours, neither of the plasma assays
for cystatin C or NGAL were predictive of AKI; however,
the urinary values of both were elevated, suggesting that
at least for these two candidate biomarkers, the urinary
test might be superior to the plasma assay for the early de-
tection of AKI.P
MPREVENTION AND TREATMENT OFAKI
Hydration
It is known that adequate hydration reduces the risk that
a patient will develop AKI.22 Typically, in postoperative
cardiac surgery patients, the problem is that of too much ex-
tracellular fluid rather than too little, such that dehydration
is less of a problem. Hypovolemia, however, is a different
issue and requires aggressive correction if end-organ perfu-
sion (and thus function) is to be preserved. Although in nor-
mal volunteers, the kidney has been shown to autoregulate
its blood flow within a mean arterial pressure range of 60 to
120 mm Hg, it is not known whether this is also the case in
patients who have recently been exposed to a period of hy-
pothermic, nonpulsatile perfusion. However, the benefits of
maintaining a cardiac index greater than 2 l ∙min1 ∙m2 in
the immediate postoperative period are widely appreciated
in cardiac surgical intensive care units,23 and uncorrected
gross hypovolemia is thus uncommon.Fluid Type
There has recently been a suggestion that synthetic
colloids based on starches might be nephrotoxic.24 It is
important to realize, however, that that study used a sec-
ond-generation starch product in an unbalanced crystalloid
carrier. Therefore, these data are not generalizable to con-
temporary North American practice. It is clear that stroke
volume optimization in high-risk general surgery patientsThe Journal of Thoracic and Careduces the length of stay,25 and data have suggested this
might also be the case in heart surgery.26
Blood Transfusion
Bleeding and blood transfusion are central issues in car-
diac surgical medicine and can account for up to 50% of the
blood products prescribed and delivered in some institu-
tions. It is known that anemia is a risk factor for AKI; how-
ever, so is the transfusion of stored blood.27 Whether the
adverse effects of transfused stored blood that were reported
in studies using nonleucodepleted blood28 will be repro-
duced in studies using leucodepleted blood is unclear. Anti-
fibrinolytics have been associated with the development of
AKI29 and also with the absence of increased risk.30 The
currently available antifibrinolytic drugs appear not to carry
any extra risk of AKI.
Dopamine Agonists
Decades of experience have shown that in low doses, do-
pamine is clearly a useful drug for weaning patients from
epinephrine infusions and generally ‘‘toning up’’ the post-
cardiotomy circulation. It is also clear from the published
data (a meta-analysis of 61 randomized ‘‘low-dose’’ [<5
mg/kg/min] dopamine renoprotection trials, including
3359 patients, concluded no benefit was present in terms
of mortality or dialysis31) that low-dose dopamine is not
beneficial when given solely for a renal indication. It is
true this drug does have natriuretic and diuretic properties,
but these should not be confused with renal protection. Fe-
noldopam (a specific DA1 agonist) has a body of data
32 sup-
porting its use for improving renal blood flow and
decreasing the incidence of AKI; however, it remains a bou-
tique therapy used by enthusiasts only, for reasons that re-
main unclear. Compared with dopamine, in particular,
fenoldopam appears to cause less atrial fibrillation.33
Diuretics
Almost all cardiac surgery patients receive loop diuretics
at some point in their hospitalization and are often also re-
ceiving these drugs chronically. Rather than studying
whether they should or should not be used, it would be
more fruitful to discuss how they should be used. Data
have suggested that infusions are associated with better out-
comes than intermittent bolus administration,34 and ongo-
ing trials are studying this exact question (S.M. Bagshaw,
personal communication, March 2011). Mannitol is com-
monly added to cardiopulmonary bypass circuit prime,
but no good data are available to support this practice.
Natriuretic Peptides
Perioperative infusions of human recombinant brain na-
triuretic peptide (nesiritide) have been shown to reduce
AKI, shorten the hospital stay, and improve 6-month sur-
vival in a randomized study of 272 coronary bypass patientsrdiovascular Surgery c Volume 143, Number 3 679
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Mwith impaired left ventricular function.35 However, the ap-
parent enthusiasm for this seemingly good result should be
balanced by the observation that in nonsurgical studies,
brain natriuretic peptide appeared to worsen renal function
in patients with heart failure,36 and a subsequent follow-up
study has not been published to confirm this finding.
Glycemic Control With Intravenous Insulin
Reabsorption of tubular glucose is an active, energy-
consuming process; thus, it is thought that reducing the met-
abolic burden in the tubules by reducing the concentration
of urinary glucose might preferentially affect intrarenal
oxygen flux. A randomized study of 1548 critically ill pa-
tients (63% of whom had undergone cardiac surgery) found
a lower incidence of renal replacement therapy and im-
proved survival with intensive (target glucose 80–110
mg/dL) compared with conventional (target 180–200
mg/dL) glycemic control.37 However, a large clinical trial
in Australia and New Zealand subsequently questioned
the benefit of tight glycemic control, suggesting no benefit
compared with a less-aggressive glucose target.38
Urinary Alkalinization
It has been suggested that cardiac surgery-associated
AKI is in large part a pigment nephropathy.39 Cold, nonpul-
satile, extracorporeal circulation with passage through suc-
tion catheters, oxygenators, bubble traps, and filters is
certainly a good recipe for hemolysis, and pink urine in
the bladder catheter bag is indeed a familiar sight. Haase
and colleagues40 conducted a preliminary trial of urinary al-
kalinization in cardiac surgery patients at high risk of AKI
and showed that in patients randomized to a tonically equiv-
alent dose of sodium bicarbonate (compared with sodium
chloride), the incidence of AKI was less in the bicarbonate
group. The urine of the bicarbonate patients was effectively
alkalinized, which might have enhanced urinary excretion
of free filtered hemoglobin. However, it is also possible
that avoiding a chloride load also has beneficial effects on
the kidney. A large follow-up trial is currently underway,
the results of which are eagerly awaited.
Renal Replacement Therapy
In North America, RRT is generally a nephrologic busi-
ness; however, in the rest of the world, continuous RRT
(eg, hemofiltration) is largely an intensive care unit treat-
ment. This disconnect has resulted because of nonclinical
issues and represents an unfortunate development. Extra-
corporeal therapy will attract an ever increasing presence
in the modern intensive care unit, as the extracorporeal phi-
losophy leans more toward earlier, partial organ assist
rather than later organ function replacement. As such, all
those involved in intensive care management will require
a working knowledge of partial cardiac assist, partial lung
assist, partial liver assist, and partial kidney assist680 The Journal of Thoracic and Cardiovascular Surgtechniques. Although continuous venovenous hemofiltra-
tion is a physiologically simple concept (it is just like a glo-
merulus), it is important to consider the potential downside
(ie, catheter placement complications, infection, bleeding,
metabolic disturbance, fluid shifts) before its initiation.41
However, it is important that this technique becomes avail-
able to the wider intensive care unit community, just as ul-
trasonography has in recent years. In surgical practice,
especially, understanding of the benefits of a zero-weight
gain approach for perioperative medicine is increasing,42
and cardiac surgeons are well placed to lead the trend to-
ward the earlier use of continuous venovenous hemofiltra-
tion in their volume-overloaded patients.CONCLUSIONS
AKI is common in cardiac surgery patients, especially
those with elevated preoperative serum creatinine who un-
dergo on-pump surgery for something other than primary
coronary artery bypass grafting. A new consensus defini-
tion, new biomarkers, new ideas about the pathophysiology,
and new ideas about its prevention and treatment are avail-
able. This is an exciting time to be in perioperative nephrol-
ogy, and our ability to identify an enriched at-risk
population clinically and further stratify them with the use
of new biomarkers makes cardiac surgery-associated AKI
a particularly attractive domain for intervention trials.References
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